Home › Companies › Axsome Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Axsome Therapeutics, Inc.’s Form 8-K, filed 2026-06-09 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Axsome Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Axsome Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-09 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Mark Saad | 28,675,654 | -- | -- | 10,286,822 | 4,815,060 | Majority: yes |
| Elect Director: Susan Mahony, Ph.D., MBA | 29,892,131 | -- | -- | 9,070,345 | 4,815,060 | Majority: yes |
| Proposal 2: Ratification of Appointment of Deloitte & Touche LLP | 43,278,147 | 14,407 | 484,982 | -- | 0 | Majority: yes |
| Proposal 3: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers | 37,818,384 | 777,937 | 366,155 | -- | 4,815,060 | Majority: yes |
Source: Axsome Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-09 — read the filing on EDGAR.
Each item below shows how the 412 asset managers that disclosed a Axsome Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Axsome Therapeutics, Inc.’s own tally for this item (“Proposal 3: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers”): 37,818,384 for, 777,937 against, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,459,766 outstanding shares: 73% for, 2% against (75% of the company cast a for/against vote).
The 408 asset managers below cast 99% of the shares they voted on this item FOR (35,333,321 for, 363,262 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,637,948 | 3 | 1 | 0 | For |
| Fidelity | 4,188,631 | 0 | 0 | 0 | For |
| BlackRock | 3,658,451 | 8,809 | 0 | 0 | For |
| Invesco | 2,382,642 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,341,440 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,163,544 | 0 | 0 | 0 | For |
| State Street | 861,945 | 1,327 | 0 | 0 | For |
| Wellington | 839,000 | 0 | 0 | 0 | For |
| Charles Schwab | 788,684 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 737,578 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 702,773 | 0 | 0 | 0 | For |
| First Trust | 564,201 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 502,996 | 0 | 0 | 0 | For |
| Putnam | 476,018 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 444,493 | 0 | 0 | 0 | For |
| Nuveen | 411,909 | 0 | 0 | 0 | For |
| Loomis Sayles | 387,740 | 0 | 0 | 0 | For |
| Northern Trust | 384,675 | 2,848 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 369,389 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 311,038 | 0 | 0 | 0 | For |
| Voya | 285,171 | 0 | 0 | 0 | For |
| Citadel | 266,615 | 0 | 0 | 0 | For |
| TIAA | 252,697 | 0 | 0 | 0 | For |
| John Hancock | 248,049 | 0 | 0 | 0 | For |
| Jackson National | 245,047 | 0 | 0 | 0 | For |
Showing the 25 largest of 408 asset managers. See all 408 in the interactive database.
Combines 7 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Axsome Therapeutics, Inc.’s own tally for this item (“Elect Director: Mark Saad”): 28,675,654 for, 10,286,822 withheld, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,459,766 outstanding shares: 56% for, 20% withheld (76% of the company cast a for/withheld vote).
The 104 asset managers below cast 100% of the shares they voted on this item FOR (12,163,702 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,261,231 | 0 | 18,694 | 0 | For |
| Fidelity | 2,528,128 | 0 | 13,900 | 0 | For |
| BlackRock | 2,051,700 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 931,652 | 0 | Abstain |
| Invesco | 853,953 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 561,179 | 0 | Abstain |
| MUTUAL FUND SERIES TRUST | 496,558 | 0 | 6,438 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 444,493 | 0 | Abstain |
| Charles Schwab | 393,406 | 0 | 110 | 0 | For |
| TIAA | 0 | 0 | 252,697 | 0 | Abstain |
| Jackson National | 212,271 | 0 | 32,776 | 0 | For |
| Putnam | 190,657 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 169,495 | 0 | Abstain |
| Manager Directed Portfolios | 168,240 | 0 | 0 | 0 | For |
| Brighthouse | 81,393 | 0 | 83,311 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 153,831 | 0 | Abstain |
| John Hancock | 11,796 | 0 | 137,462 | 0 | Abstain |
| Loomis Sayles | 0 | 0 | 139,821 | 0 | Abstain |
| Franklin Custodian Funds | 0 | 0 | 128,461 | 0 | Abstain |
| Voya | 0 | 0 | 116,066 | 0 | Abstain |
| Waddell & Reed | 0 | 0 | 103,315 | 0 | Abstain |
| Royce | 93,662 | 0 | 0 | 0 | For |
| Equitable | 58,901 | 0 | 34,249 | 0 | For |
| Hartford | 91,430 | 0 | 0 | 0 | For |
| Nuveen | 0 | 0 | 76,149 | 0 | Abstain |
Showing the 25 largest of 104 asset managers. See all 104 in the interactive database.
Combines 8 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Axsome Therapeutics, Inc.’s own tally for this item (“Elect Director: Susan Mahony, Ph.D., MBA”): 29,892,131 for, 9,070,345 withheld, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,459,766 outstanding shares: 58% for, 18% withheld (76% of the company cast a for/withheld vote).
The 104 asset managers below cast 100% of the shares they voted on this item FOR (12,427,080 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,263,496 | 0 | 16,429 | 0 | For |
| Fidelity | 2,528,128 | 0 | 13,900 | 0 | For |
| BlackRock | 2,051,700 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 931,652 | 0 | Abstain |
| Invesco | 853,953 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 561,179 | 0 | Abstain |
| MUTUAL FUND SERIES TRUST | 496,558 | 0 | 6,438 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 444,493 | 0 | Abstain |
| Charles Schwab | 393,516 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 252,697 | 0 | Abstain |
| Jackson National | 212,271 | 0 | 32,776 | 0 | For |
| Putnam | 190,657 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 169,495 | 0 | Abstain |
| Manager Directed Portfolios | 168,240 | 0 | 0 | 0 | For |
| Brighthouse | 81,393 | 0 | 83,311 | 0 | Abstain |
| Columbia Threadneedle | 153,831 | 0 | 0 | 0 | For |
| John Hancock | 11,796 | 0 | 137,462 | 0 | Abstain |
| Loomis Sayles | 0 | 0 | 139,821 | 0 | Abstain |
| Franklin Custodian Funds | 0 | 0 | 128,461 | 0 | Abstain |
| Voya | 0 | 0 | 116,066 | 0 | Abstain |
| Waddell & Reed | 0 | 0 | 103,315 | 0 | Abstain |
| Royce | 93,662 | 0 | 0 | 0 | For |
| Equitable | 58,901 | 0 | 34,249 | 0 | For |
| Hartford | 91,430 | 0 | 0 | 0 | For |
| Nuveen | 0 | 0 | 76,149 | 0 | Abstain |
Showing the 25 largest of 104 asset managers. See all 104 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Axsome Therapeutics, Inc.’s own tally for this item (“Proposal 2: Ratification of Appointment of Deloitte & Touche LLP”): 43,278,147 for, 14,407 against, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,459,766 outstanding shares: 84% for, 0.1% against (84% of the company cast a for/against vote).
The 103 asset managers below cast 100% of the shares they voted on this item FOR (16,295,166 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,279,925 | 0 | 0 | 0 | For |
| Fidelity | 2,542,028 | 0 | 0 | 0 | For |
| BlackRock | 2,051,700 | 0 | 0 | 0 | For |
| T. Rowe Price | 931,652 | 0 | 0 | 0 | For |
| Invesco | 853,953 | 0 | 0 | 0 | For |
| First Trust | 561,179 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 502,996 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 444,493 | 0 | 0 | 0 | For |
| Charles Schwab | 393,516 | 0 | 0 | 0 | For |
| TIAA | 252,697 | 0 | 0 | 0 | For |
| Jackson National | 245,047 | 0 | 0 | 0 | For |
| Putnam | 190,657 | 0 | 0 | 0 | For |
| Principal | 169,495 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 168,240 | 0 | 0 | 0 | For |
| Brighthouse | 161,116 | 0 | 3,588 | 0 | For |
| Columbia Threadneedle | 153,831 | 0 | 0 | 0 | For |
| John Hancock | 149,258 | 0 | 0 | 0 | For |
| Loomis Sayles | 139,821 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 128,461 | 0 | 0 | 0 | For |
| Voya | 116,066 | 0 | 0 | 0 | For |
| Waddell & Reed | 103,315 | 0 | 0 | 0 | For |
| Royce | 93,662 | 0 | 0 | 0 | For |
| Equitable | 93,150 | 0 | 0 | 0 | For |
| Hartford | 91,430 | 0 | 0 | 0 | For |
| Nuveen | 76,149 | 0 | 0 | 0 | For |
Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.
Ranked by the number of Axsome Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 51,459,766 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.01% |
| 2 | Fidelity | 8.14% |
| 3 | BlackRock | 7.13% |
| 4 | Invesco | 4.63% |
| 5 | T. Rowe Price | 4.55% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 2.26% |
| 7 | State Street | 1.68% |
| 8 | Wellington | 1.63% |
| 9 | Charles Schwab | 1.53% |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.43% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Herriot Tabuteau, M.D. | 17.47% | DEF14A |
| Antecip Capital LLC | 14.27% | DEF14A |
| Vanguard Group | 8.09% | 13F |
| BlackRock | 7.60% | 13F |
| FMR (Fidelity) | 3.05% | 13F |
| T. Rowe Price | 2.56% | 13F |
| Invesco | 2.52% | 13F |
| Geode Capital | 2.26% | 13F |
| Wellington Management | 2.23% | 13F |
| State Street | 1.92% | 13F |
Percentages above are of 51,459,766 shares outstanding, as reported by Axsome Therapeutics, Inc. on its Form 10-Q dated 2026-04-27 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Axsome Therapeutics, Inc.’s 10-Q dated 2026-04-27. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Axsome Therapeutics, Inc.'s shareholder meeting held 2026-06-05, in the 2025-2026 proxy season, 412 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,885 separate fund positions. On the most widely held item on that ballot — To approve, by non-binding advisory vote, the compensation of our named executive officers. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Axsome Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-09.
Axsome Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).